Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;41(9):2233-2234.
doi: 10.1111/liv.15010. Epub 2021 Jul 20.

Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor

Tomoharu Yamada  1 , Tatsuya Minami  1 , Ryosuke Tateishi  1 , Kazuhiko Koike  1
Affiliations
Comment

Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor

Tomoharu Yamada et al. Liver Int. 2021 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Rimassa L, Worns MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver Int. 2020;40(8):1800-1811.
    1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905.
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.
    1. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4. https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm
    1. Lee MS, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808-820.

LinkOut - more resources